课题基金 / 基金详情

Precision methylation biomarkers linked to cancer disparities

Precision methylation biomarkers linked to cancer disparities
精确甲基化生物标志物与癌症差异相关
批准号:
9905229
负责人:
Rafael Guerrero-Preston
金额:
$20.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-24 至 2020-05-31

项目摘要

项目成果

Rafael Guerrero-Preston的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary No woman should die of cervical cancer, yet cervical cancer is the third leading malignancy among women in the world, after breast cancer and colorectal cancer. Cervical cancer is also one of the tumors in which the most glaring disparities exist worldwide. Cervical cancer incidence and mortality has been higher for decades among Latinas in the United States (US). However, a recently published study revealed that cervical cancer death rates among White and Black women in the US are much higher than previously thought, after adjusting for the number of hysterectomies performed. Black women are dying from cervical cancer at a rate 77% higher than previously thought, and white women are dying at a rate 47% higher. The disparity in cervical cancer mortality rates by race doubled, from 2.7 to 5.4 per 100,000 women, after removing women with hysterectomies from mortality calculations. Presumably, the same is the case for Latina women, but there is currently no data available to verify if this is the case. The use of cytology screening (Pap smear) and oncogenic Human papilloma Virus (HPV+) genotyping are effective in identifying women who may be at risk for cervical cancer, but cannot be used to predict who is more likely to develop cervical carcinoma. Current standard of practice in the US for women with persistent HPV+ infection and abnormal Pap is referral to colposcopy and subsequent biopsy. However, most of these biopsies (55%-70%) are performed in women without clinical disease The goal of this project is to demonstrate the feasibility for the commercialization of the CervicalMethDx Test, a precision methylation for the cervical cancer screening space. We will focus on patients with persistent oncogenic Human Papilloma Virus (HPV+) infection, who are referred into colposcopy and subsequent biopsy, even when most will have a normal biopsy. We are partnering with David Sidransky's research laboratory to optimize the CervicalMethDx Test and with the Education and Outreach Department of the Johns Hopkins Sidney Kimmel Cancer Center to introduce precision epigenetic services to residents of low-income neighborhoods in Baltimore. Efficient triage of HPV+ women into colposcopy will decrease unnecessary biopsies, improve health care quality, decrease health care costs, and reduce existing cervical cancer mortality disparities in the US.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Precision DNA methylation test to reduce oral cancer disparities in African Americans patients residing in low-resource settings
  • 批准号:
    10706376
  • 项目类别:
  • 资助金额:
    $29.25万
  • 财政年份:
    2023
  • 负责人:
    Rafael Guerrero-Preston
  • 依托单位:
Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America
  • 批准号:
    10258144
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2021
  • 负责人:
    Rafael Guerrero-Preston
  • 依托单位:
Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America
  • 批准号:
    10654910
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2021
  • 负责人:
    Rafael Guerrero-Preston
  • 依托单位:
Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America
  • 批准号:
    10666709
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2021
  • 负责人:
    Rafael Guerrero-Preston
  • 依托单位:
海外基金